Navigation Links
Delcath to Present at the 30th Annual Canaccord Global Growth Conference
Date:8/4/2010

NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that management will present at the 30th Annual Canaccord Global Growth Conference in Boston, MA on Thursday, August 12, 2010 at 8:30 a.m. ET.  Mr. Eamonn Hobbs, Chief Executive Officer, and Mr. David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only. Delcath will offer a live audio webcast of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentation will be available for 30 days, also at www.delcath.com.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, market acceptance and the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, actions by the FDA or other regulatory agencies  and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... YORK , Feb. 17, 2017  BioDigital, ... today the partnership of their 3D body mapping ... healthcare IT.  The new integration will be used ... an interactive model of the human body. BioDigital ... saves clinicians time, while also increasing the precision ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
(Date:2/16/2017)... , Feb. 16, 2017 Research ... Markets for Emerging Medical Device Technologies" report to their ... ... valves, open procedures, general instruments, non-drug coated implantables, large endoscopes, ... been in use over the last two to three decades ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... Tx (PRWEB) , ... February 17, 2017 , ... ... revenue cycle management services, announced today that Karen Pilley has been promoted to ... is critical in today’s shifting healthcare paradigm – a shift that demands the ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Officer, George Rogers, was named to Staffing Industry Analysts' 2017 "Staffing 100 North ... those who have made notable contributions to the staffing industry over the last ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Like most hospitals ... readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), the return ... key focus area for hospitals across the nation. While many providers are struggling to ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, a ... business owners in and around the Hampton Roads metropolitan region, is joining the ... of domestic violence. , There are multiple categories of domestic violence – physical ...
Breaking Medicine News(10 mins):